We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Immune System's Requirements for Protection Against SARS-CoV-2 Defined
News

Immune System's Requirements for Protection Against SARS-CoV-2 Defined

Immune System's Requirements for Protection Against SARS-CoV-2 Defined
News

Immune System's Requirements for Protection Against SARS-CoV-2 Defined

Credit: mattthewafflecat/ Pixabay
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Immune System's Requirements for Protection Against SARS-CoV-2 Defined"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Since the novel coronavirus emerged at the end of last year, scientists around the world — including Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan Barouch, MD, PhD — have been developing vaccines to protect against COVID-19 and to put an end to the global pandemic. As of November 2020, three pharmaceutical companies released early data showing high rates of protection in Phase 3 human trials for their vaccines, but questions remain about how the body develops and maintains immunity after vaccination or infection.

In a new paper in the journal Nature, Barouch, Director of BIDMC's Center for Virology and Vaccine Research, and colleagues shed light on the role of antibodies and immune cells in protection against SARS-CoV-2, the virus that causes COVID-19, in rhesus macaques. "In this study, we define the role of antibodies versus T cells in protection against COVID-19 in monkeys. We report that a relatively low antibody titer (the concentration of antibodies in the blood) is needed for protection," said Barouch. "Such knowledge will be important in the development of next-generation vaccines, antibody-based therapeutics, and public health strategies for COVID-19."

Building on previous findings that SARS-CoV-2 infection protects rhesus monkeys from re-exposure, Barouch and colleagues purified and collected antibodies from animals that had recovered from infection. They administered the antibodies at various concentrations to 12 uninfected macaques and observed that protection against SARS-CoV-2 challenge was dose dependent. Animals that received higher amounts of antibodies were protected more completely, while animals that received lower amounts of antibodies were protected less well. Similarly, when the researchers administered various concentrations of the purified antibodies to 6 macaques with active SARS-CoV-2 infection, those given higher doses demonstrated more rapid viral control.

In a second set of experiments, Barouch and colleagues evaluated the role of specific immune cells — CD8+ T cells — in contributing to protection against the virus by removing these cells from animals that had recovered from SARS-CoV-2 infection. Removal of these immune cells left the animals vulnerable to infection after re-exposure to SARS-CoV-2.

"Our data define the role of antibodies and T cells in protection against COVID-19 in monkeys. Antibodies alone can protect, including at relatively low levels, but T cells are also helpful if antibody levels are insufficient," said Barouch, who is also Professor of Medicine at Harvard Medical School, and a member of the Ragon Institute of MGH, MIT, and Harvard. ";Such correlates of protection are important given the recent successful vaccine results from human trials, and the likelihood that these and other vaccines will become widely available in the spring; as a result future vaccines may need to be licensed based on immune correlates rather than clinical efficacy."

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.


Advertisement